Lenvatinib: Phase III data

The double-blind, international Phase III SELECT (Study 303) trial in 392 patients with radioiodine-refractory differentiated thyroid cancer and radiographic evidence of disease progression within the prior 12 months showed that once-daily 24 mg oral lenvatinib met the primary endpoint of improving PFS vs. placebo. The most common adverse events reported were hypertension, diarrhea, decreased appetite, decreased weight and nausea. This year, Eisai plans to submit regulatory applications for lenvatinib to treat radioiodine-refractory differentiated thyroid cancer in the U.S., Europe and Japan. ...